Osborn D A, Jeffery H E, Cole M
RPA Newborn Care, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, Australia, 2050.
Cochrane Database Syst Rev. 2005 Jul 20(3):CD002059. doi: 10.1002/14651858.CD002059.pub2.
Neonatal abstinence syndrome (NAS) due to opiate withdrawal may result in disruption of the mother-infant relationship, sleep-wake abnormalities, feeding difficulties, weight loss and seizures. Treatments used to ameliorate symptoms and reduce morbidity include opiates, sedatives and non-pharmacological treatments.
To assess the effectiveness and safety of using an opiate, compared to a sedative or non-pharmacological treatment, for treatment of NAS due to withdrawal from opiates.
The previous review was updated with additional searches of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 1, 2005), MEDLINE (1966-December 2004) and EMBASE (1980-December 2004) supplemented by searches of conference abstracts and citation lists of published articles.
Trials enrolling infants with NAS born to mothers with an opiate dependence, with > 80% follow up and using random or quasi-random allocation to opiate or control. Control could include an opiate, sedative or non-pharmacological treatment.
Each author assessed study quality and extracted data independently. Primary outcomes included control of symptoms, seizure occurrence, mortality and neurodevelopment. Treatment effect was expressed using relative risk (RR), risk difference (RD), mean difference (MD) and weighted mean difference (WMD). Meta-analysis was performed using a fixed effect model.
Seven studies enrolling a total of 585 infants met inclusion criteria (Carin 1983; Finnegan 1984; Jackson 2004; Kaltenbach 1986; Kandall 1983; Khoo 1995; Madden 1977); however, two (Finnegan 1984; Kaltenbach 1986) may be sequential reports that include some identical patients. The studies enrolled infants of mothers who had used opiates with or without other drugs during pregnancy. Methodological concerns included the use of quasi-random rather than random patient allocation methods in three studies; sizeable, largely unexplained differences in reported numbers allocated to each group in four studies; and imbalances in group characteristics after randomisation in one study. Opiate (morphine) vs supportive care only: One study (Khoo 1995) found no significant effect on treatment failure (RR 1.29, 95% CI 0.41, 4.07), a significant increase in hospital stay (MD 15.0 days, 95% CI 8.9, 21.1) and significant reductions in time to regain birthweight (MD -2.8 days, 95% -5.3, -0.3) and duration of supportive care (MD -197.2 minutes/day, 95% CI -274.2, -120.3). Opiate vs phenobarbitone: Meta-analysis of four studies found no significant difference in treatment failure (typical RR 0.76, 95% CI 0.51, 1.11). One of these studies (Finnegan 1984) reported that opiate treatment resulted in a significant reduction in treatment failure among infants of mothers who had used only opiates; however, as this was a post-hoc analysis, this result should be interpreted with caution. One study (Jackson 2004) reported a significant reduction in duration of treatment and admission to the nursery for infants receiving morphine compared to phenobarbitone. One study (Kandall 1983) reported a reduction in seizures, of borderline statistical significance, with the use of opiate. Opiate vs diazepam: Meta-analysis of two studies found a significant reduction in treatment failure (RR 0.43, 95% CI 0.23, 0.80) with the use of opiate. No study reported neurodevelopment by allocated treatment group.
AUTHORS' CONCLUSIONS: Opiates, as compared to supportive care only, appear to reduce the time to regain birth weight and reduce the duration of supportive care, but increase the duration of hospital stay; there is no evidence of effect on treatment failure. When compared to phenobarbitone, opiates may reduce the incidence of seizures but, overall, there is no evidence of effect on treatment failure. One study reported a reduction in duration of treatment and nursery admission for infants on morphine. When compared to diazepam, opiates reduce the incidence of treatment failure. A post-hoc analysis generates the hypothesis that treatment effects may vary according to whether the population includes infants born to all opiate users (i.e. with or without other drug exposure) or is restricted to infants of mothers who used opiates only. In view of the methodologic limitations of the included studies the conclusions of this review should be treated with caution.
因阿片类药物戒断导致的新生儿戒断综合征(NAS)可能会破坏母婴关系,导致睡眠 - 觉醒异常、喂养困难、体重减轻和癫痫发作。用于改善症状和降低发病率的治疗方法包括阿片类药物、镇静剂和非药物治疗。
评估与镇静剂或非药物治疗相比,使用阿片类药物治疗因阿片类药物戒断引起的NAS的有效性和安全性。
通过对Cochrane对照试验中央注册库(CENTRAL,Cochrane图书馆,2005年第1期)、MEDLINE(1966年 - 2004年12月)和EMBASE(1980年 - 2004年12月)进行额外检索,并辅以会议摘要检索和已发表文章的参考文献列表更新了之前的综述。
纳入母亲有阿片类药物依赖所生的患有NAS的婴儿的试验,随访率> 80%,并使用随机或半随机分配至阿片类药物组或对照组。对照组可包括阿片类药物、镇静剂或非药物治疗。
每位作者独立评估研究质量并提取数据。主要结局包括症状控制、癫痫发作、死亡率和神经发育。治疗效果用相对危险度(RR)、危险度差值(RD)、均数差值(MD)和加权均数差值(WMD)表示。采用固定效应模型进行Meta分析。
七项共纳入585名婴儿的研究符合纳入标准(Carin 1983;Finnegan 1984;Jackson 2004;Kaltenbach 1986;Kandall 1983;Khoo 1995;Madden 1977);然而,其中两项研究(Finnegan 1984;Kaltenbach 1986)可能是系列报告,包含一些相同的患者。这些研究纳入了孕期使用或未使用其他药物的阿片类药物母亲的婴儿。方法学问题包括三项研究使用半随机而非随机患者分配方法;四项研究中每组分配的报告人数存在相当大且大多无法解释的差异;一项研究随机分组后组间特征不均衡。仅阿片类药物(吗啡)与支持性护理对比:一项研究(Khoo 1995)发现对治疗失败无显著影响(RR 1.29,95% CI 0.41,4.07),住院时间显著增加(MD 15.0天,95% CI 8.9,21.1),恢复出生体重时间显著缩短(MD -2.8天,95% -5.3,-0.3)以及支持性护理持续时间显著缩短(MD -197.2分钟/天,95% CI -274.2,-120.3)。阿片类药物与苯巴比妥对比:四项研究的Meta分析发现治疗失败无显著差异(典型RR 0.76,95% CI 0.51,1.11)。其中一项研究(Finnegan 1984)报告阿片类药物治疗使仅使用阿片类药物母亲的婴儿治疗失败率显著降低;然而,由于这是一项事后分析,该结果应谨慎解读。一项研究(Jackson 2004)报告与苯巴比妥相比,接受吗啡治疗的婴儿治疗持续时间和入住新生儿重症监护室的时间显著缩短。一项研究(Kandall 1983)报告使用阿片类药物可使癫痫发作减少,具有临界统计学意义。阿片类药物与地西泮对比:两项研究的Meta分析发现使用阿片类药物可使治疗失败显著降低(RR 0.43,95% CI 0.23,0.80)。没有研究按分配的治疗组报告神经发育情况。
与仅支持性护理相比,阿片类药物似乎可缩短恢复出生体重的时间并缩短支持性护理的持续时间,但会增加住院时间;没有证据表明对治疗失败有影响。与苯巴比妥相比,阿片类药物可能会降低癫痫发作的发生率,但总体而言,没有证据表明对治疗失败有影响。一项研究报告使用吗啡的婴儿治疗持续时间和入住新生儿重症监护室的时间缩短。与地西泮相比,阿片类药物可降低治疗失败的发生率。一项事后分析提出假设,即治疗效果可能因人群是包括所有阿片类药物使用者所生的婴儿(即有或无其他药物暴露)还是仅限于仅使用阿片类药物母亲的婴儿而有所不同。鉴于纳入研究的方法学局限性,本综述的结论应谨慎对待。